GEN Exclusives

More »

GEN Poll

Nov 28, 2011

Geron’s hESC Assets

Geron, a pioneer in stem cell research founded in 1990, announced on November 14 that it was halting its stem cell therapeutic programs and is seeking partners for these assets. Full story here. Geron had been developing differentiated human embryonic stem cells (hESCs), with its lead product in Phase I for spinal cord injury. While BioTime could be a potential buyer, the firm is currently focused on research tools. Advanced Cell Technology (ACT) remains the only company left with ongoing clinical trials involving hESCs. But ACT doesn’t have a lot of cash, and the fact is that Geron had the most money. Given Geron’s financial strengths and longstanding scientific expertise, do you think another organization has what it takes to succeed where Geron failed?

Do you think Geron will find a partner for its human embryonic stem cell therapeutic programs?



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »